Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.02, Briefing.com reports. The company had revenue of $33.80 million during the quarter, compared to analysts’ expectations of $31.76 million. The firm’s revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.21) EPS.
Halozyme Therapeutics (HALO) traded down 3.56% during mid-day trading on Thursday, reaching $12.20. The company’s stock had a trading volume of 798,493 shares. The stock’s market cap is $1.73 billion. Halozyme Therapeutics has a 52-week low of $8.18 and a 52-week high of $15.20. The company has a 50 day moving average of $13.28 and a 200-day moving average of $13.12.
Several equities analysts have recently commented on the company. BMO Capital Markets assumed coverage on Halozyme Therapeutics in a research note on Monday, April 17th. They set a “market perform” rating and a $14.00 target price for the company. Zacks Investment Research lowered Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 3rd. ValuEngine raised Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 16th. Finally, Barclays PLC reaffirmed an “overweight” rating and issued a $16.00 target price on shares of Halozyme Therapeutics in a research report on Friday, June 23rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $14.88.
A number of hedge funds have recently added to or reduced their stakes in HALO. LLBH Private Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics during the first quarter worth $2,021,000. Pictet Asset Management Ltd. bought a new stake in shares of Halozyme Therapeutics during the first quarter worth about $18,888,000. Bank of New York Mellon Corp increased its stake in shares of Halozyme Therapeutics by 27.3% in the first quarter. Bank of New York Mellon Corp now owns 1,806,490 shares of the biopharmaceutical company’s stock worth $23,412,000 after buying an additional 387,486 shares in the last quarter. Chicago Equity Partners LLC increased its stake in shares of Halozyme Therapeutics by 1.7% in the first quarter. Chicago Equity Partners LLC now owns 170,030 shares of the biopharmaceutical company’s stock worth $2,204,000 after buying an additional 2,770 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of Halozyme Therapeutics by 22.5% in the first quarter. Wells Fargo & Company MN now owns 303,626 shares of the biopharmaceutical company’s stock worth $3,935,000 after buying an additional 55,719 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
